CRISPR-based oligo recombineering prioritizes apicomplexan cysteines for drug discovery.

Benns, HJ; Storch, M; Falco, JA; Fisher, FR; Tamaki, F; Alves, E; Wincott, CJ; Milne, R; Wiedemar, N; Craven, G; +7 more... Baragaña, B; Wyllie, S; Baum, J; Baldwin, GS; Weerapana, E; Tate, EW; Child, MA; (2022) CRISPR-based oligo recombineering prioritizes apicomplexan cysteines for drug discovery. Nature Microbiology, 7 (11). pp. 1891-1905. ISSN 2058-5276 DOI: https://doi.org/10.1038/s41564-022-01249-y

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1038/s41564-022-01249-y

Abstract

Share

Download

Filename: Benns et al, 2022.pdf

Licence: Creative Commons: Attribution 4.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar